Concordance of Somatic Whole-Exome Sequencing and Germline Genotyping of DPYD to Screen for Dihydropyrimidine Dehydrogenase Deficiency
JCO Oncology Advances · 2026-10 · 3 (4)
DOI: 10.1200/oa-26-00013 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-10. Verfasst von Aditya Sharma und 9 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Purpose
Fluoropyrimidines are among the most commonly used chemotherapies in multiple solid tumor malignancies. They are primarily metabolized by the enzyme dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene. Decreased function variants of DPD, often because of pathogenic variants in DPYD which are seen in 2%-8% of the North American and European populations, can lead to increased frequency and severity of adverse events, including death. Despite this, DPYD genotyping is not currently widely practiced in the United States.
Methods
We sought to identify the role of whole-exome sequencing (WES) of somatic tumor samples as an alternative to the traditional germline genotyping typically performed on peripheral blood samples.
Results
Of the 115 patients retrospectively analyzed, we demonstrated a 100% concordance between germline genotyping and our in-house somatic WES platform, known as DHCancerSeq, in the identification of pathogenic DPYD variants.
Conclusion
Although not a replacement for germline genotyping, as WES is limited in its ability to identify causative intronic variants, such as HapB3, and it can be affected by copy number events, there may be a role in screening for pathogenic DPYD variants via somatic WES.
Zitieren
APA
Sharma, A., Green, D., Khan, W., Shah, N., Lansigan, F., Saigal, S., Deharvengt, S., Primorac, D., Brooks, G. A., & Shah, P. (2026). Concordance of Somatic Whole-Exome Sequencing and Germline Genotyping of DPYD to Screen for Dihydropyrimidine Dehydrogenase Deficiency. JCO Oncology Advances, 3(4). https://doi.org/10.1200/oa-26-00013
Vancouver
Sharma A, Green D, Khan W, Shah N, Lansigan F, Saigal S, et al. Concordance of Somatic Whole-Exome Sequencing and Germline Genotyping of DPYD to Screen for Dihydropyrimidine Dehydrogenase Deficiency. JCO Oncology Advances. 2026;3(4). doi:10.1200/oa-26-00013
BibTeX
@article{Sharma2026,
author = {Sharma, Aditya and Green, Donald and Khan, Wahab and Shah, Nidhi and Lansigan, Frederick and Saigal, Sonia and Deharvengt, Sophie and Primorac, Dragan and Brooks, Gabriel A. and Shah, Parth},
title = {Concordance of Somatic Whole-Exome Sequencing and Germline Genotyping of DPYD to Screen for Dihydropyrimidine Dehydrogenase Deficiency},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {4},
doi = {10.1200/oa-26-00013}
}
EUVIMED